Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period. The growth was primarily driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. TONMYA recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%. This performance underscores the strong market acceptance of the first new fibromyalgia treatment in more than 15 years.
The commercial progress is further bolstered by TONMYA's broad payer coverage, which currently represents approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. Coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027. This expanding access is crucial for reaching more patients and sustaining revenue growth.
Beyond the commercial success, Tonix continues to advance its clinical pipeline, focusing on addressing high unmet medical needs in central nervous system (CNS) and immunology. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD). This trial is part of Tonix's strategy to maximize the science behind TONMYA, which contains cyclobenzaprine, and explore its potential in other CNS indications. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. This program highlights the company's expansion into immunology, with TNX-4800 being a monoclonal antibody candidate for Lyme disease prophylaxis.
The company ended the quarter with approximately $176.2 million in cash and cash equivalents. Management stated that these resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides a solid foundation for ongoing commercial activities and pipeline development.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on CNS and immunology treatments. Its commercial infrastructure supports TONMYA and its acute migraine products, Zembrace SymTouch and Tosymra. The company is also advancing a pipeline that includes TNX-2900 for Prader-Willi syndrome, a rare disease, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These candidates are investigational drugs or biologics, and their efficacy and safety have not been established.
The strong quarterly results and continued pipeline progress position Tonix as a key player in addressing chronic pain and CNS disorders. With TONMYA's rapid uptake and expanding coverage, the company is well-positioned to capture a significant share of the fibromyalgia market. As the company advances its clinical programs, its robust cash position ensures it can sustain momentum and deliver on its strategic objectives.
